Aimmune Class Action Survey

1. Did you own shares of Aimmune common stock as of September 14, 2020 (the date Aimmune filed its Recommendation Statement for the tender offer)?

Yes
No
Do not know

2. Were your Aimmune shares cashed out for the merger consideration ($34.50 in cash) when Nestlé completed the merger?

Yes
No
Do not know

3. Would you or would you not have tendered your shares if you had known that the financial projections Aimmune’s financial advisors used to render their fairness opinions on the merger (referred to in the Recommendation Statement as the “Company Management Projections”) were based on a Palforzia treatment period that was shorter than required?

I would have tendered
I would not have tendered
Do not know

4. Would you or would you not have tendered your shares if you had known that the financial projections Aimmune’s financial advisors used to render their fairness opinions on the merger (referred to in the Recommendation Statement as the “Company Management Projections”) did not reflect management’s best estimates of the expected future results of the Company?

I would have tendered
I would not have tendered
Do not know

5. Would you or would you not have tendered your shares if the merger consideration you received was less than the valuation ranges that Aimmune’s financial advisors calculated?

I would have tendered
I would not have tendered
Do not know

6. Would you or would you not have tendered your shares if Aimmune had not obtained a fairness opinion from a financial advisor?

I would have tendered
I would not have tendered
Do not know

7. Would you be interested in attending the class action jury trial anticipated to start on January 13, 2025?

Yes
No
Do not know

Provide Contact Information

Name *

Phone